- Home
- MODD vs CNTB Comparison
MODD vs CNTB Comparison
Compare MODD & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- CNTB
- Stock Information
- Founded
- MODD 1998
- CNTB 2012
- Country
- MODD United States
- CNTB United States
- Employees
- MODD N/A
- CNTB N/A
- Industry
- MODD Industrial Specialties
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- CNTB Health Care
- Exchange
- MODD Nasdaq
- CNTB Nasdaq
- Market Cap
- MODD 46.3M
- CNTB 54.4M
- IPO Year
- MODD N/A
- CNTB 2021
- Fundamental
- Price
- MODD $0.70
- CNTB $1.81
- Analyst Decision
- MODD
- CNTB Strong Buy
- Analyst Count
- MODD 0
- CNTB 2
- Target Price
- MODD N/A
- CNTB $7.50
- AVG Volume (30 Days)
- MODD 70.8K
- CNTB 168.9K
- Earning Date
- MODD 08-14-2025
- CNTB 08-13-2025
- Dividend Yield
- MODD N/A
- CNTB N/A
- EPS Growth
- MODD N/A
- CNTB N/A
- EPS
- MODD N/A
- CNTB N/A
- Revenue
- MODD N/A
- CNTB $1,965,000.00
- Revenue This Year
- MODD N/A
- CNTB N/A
- Revenue Next Year
- MODD N/A
- CNTB N/A
- P/E Ratio
- MODD N/A
- CNTB N/A
- Revenue Growth
- MODD N/A
- CNTB N/A
- 52 Week Low
- MODD $0.63
- CNTB $0.51
- 52 Week High
- MODD $2.65
- CNTB $2.86
- Technical
- Relative Strength Index (RSI)
- MODD 43.81
- CNTB 46.67
- Support Level
- MODD $0.69
- CNTB $1.77
- Resistance Level
- MODD $0.75
- CNTB $2.46
- Average True Range (ATR)
- MODD 0.04
- CNTB 0.27
- MACD
- MODD 0.00
- CNTB -0.07
- Stochastic Oscillator
- MODD 16.48
- CNTB 5.80
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.